A central question in the cell biology relevant to Parkinson's disease (PD) is the roles for normal and pathogenic forms of alpha-synuclein protein in neurons and neurodegeneration. Recent evidence showed that alpha-synuclein is phosphorylated in Lewy body, a hallmark of pathogenesis of PD, and phosphorylation of alpha-synuclein is critical in mediating neurotoxicity. However, the mechanisms or cellular pathways that lead to alpha-synuclein phosphorylation, cytotoxicity, and nigral degeneration in PD are not clear. Recent discovery of mutations of LRRK2 which cause familial PD presents an opportunity to identify such cellular mechanisms or pathways. The genetic studies indicated that the mutations of LRRK2 cause the most common autosomal dominant PD to date. Although the patients with LRRK2 mutations all exhibited typical PD, the postmortem studies revealed neuro-pathological heterogeneity as shown in neurodegeneration, formation of Lewy bodies, or neurofibrillary tangles. LRRK2 encodes a large complex protein (280kD) containing several conserved domains such as sequence for Ras GTPase and MAPKKK kinase. Mutations of LRRK2 (such as R1441G) that are associated with PD are located in those domains, and likely cause altered biochemical activities of LRRK2 with deregulation of related cellular pathways. This proposal aims to 1) detect LRRK2-mediated cellular functions or pathways and to test the hypothesis of the phosphorylation of alpha-synuclein by LRRK2 kinase activity; 2) and to investigate the pathogenic mechanisms of familial PD mutation R1441G of LRRK2. To accomplish these goals, we generated transgenic mice producing epitope-tagged LRRK2 wild type or mutant which allows us to isolate LRRK2-associated protein complexes under normal and pathological conditions. These mice provide unique tools to assess the phosphorylation of alpha-synuclein (or other substrates) by LRRK2 kinase activity and to study pathogenesis of PD in vivo. In addition, we developed a specific anti-LRRK2 antibody which allows us to detect the expression and localization of endogenous LRRK2. These important reagents will help us uncover the cellular functions or pathways implicated in neuropathogenesis of PD. It will also reveal roles of LRRK2 in regulating or interacting with other molecular pathways. This proposal will provide valuable information for PD therapeutic design directed towards enzymatic activity of LRRK2. ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS055683-02
Application #
7230313
Study Section
Special Emphasis Panel (ZNS1-SRB-G (04))
Program Officer
Murphy, Diane
Project Start
2006-04-26
Project End
2008-01-31
Budget Start
2007-02-01
Budget End
2008-01-31
Support Year
2
Fiscal Year
2007
Total Cost
$185,158
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Neurology
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Dehay, Benjamin; Martinez-Vicente, Marta; Caldwell, Guy A et al. (2013) Lysosomal impairment in Parkinson's disease. Mov Disord 28:725-32
Sepulveda, Bryan; Mesias, Roxana; Li, Xianting et al. (2013) Short- and long-term effects of LRRK2 on axon and dendrite growth. PLoS One 8:e61986
Friedman, Lauren G; Lachenmayer, M Lenard; Wang, Jing et al. (2012) Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of ?-synuclein and LRRK2 in the brain. J Neurosci 32:7585-93
Li, Xianting; Wang, Qing Jun; Pan, Nina et al. (2011) Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 6:e17153
Yue, Zhenyu; Lachenmayer, M Lenard (2011) Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Mov Disord 26:1386-97
Liu, Min; Dobson, Brittany; Glicksman, Marcie A et al. (2010) Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry 49:2008-17
Li, Xianting; Patel, Jyoti C; Wang, Jing et al. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 30:1788-97
Yue, Zhenyu (2009) LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles. FEBS J 276:6445-54
Zhong, Yun; Wang, Qing Jun; Li, Xianting et al. (2009) Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol 11:468-76
Li, Xianting; Tan, Yin-Cai; Poulose, Shibu et al. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103:238-47